H. Lee Moffitt Cancer Center and Research Institute: Myeloproliferative Disorders trials

The registry lists 10 Myeloproliferative Disorders studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 8Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)CompletedNCT05177211Phase 2Results posted
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
• Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4Results posted
• Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN NeoplasmsActive, not recruitingNCT05732961Phase 2
• Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative NeoplasmsTerminatedNCT05127174Phase 1
• Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow TransplantTerminatedNCT00005852Phase 2
• Bone Marrow Transplant in Treating Patients With Hematologic CancersCompletedNCT00005797Phase 2
• Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow TransplantationTerminatedNCT00005641Phase 2
• Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersCompletedNCT00005622Phase 2